Brukinsa, a BTK inhibitor in Baiji Shenzhou, is under review in Europe for the treatment of Fahrenheit polycyloproteinemia
-
Last Update: 2020-07-12
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Brukinsa (zanubrutinib, Zebtinib), a BTK small molecule inhibitor developed by Baiji Shenzhou, has been censored by European regulators to treat patients with Fahrenheit polycyteproteinemia (WM)WM is a rarelymphoma, accounting for about 1% of all non-Hodgkin lymphoma, and is usually slow afterdiagnosisin Europe, wm incidence is about 7 cases per 1 million men and 4 cases per 1 million womenBrukinsa is a small molecule inhibitor of Bruton tyrosine kinase (BTK) and is currently being used as a monotherapy or combination therapy strategy in a wide range of key clinical programs to treat other B-cell malignanciesthe drug is the first Chinese anticancer drug approved by theFDA, which last year approved the drug for the treatment of cell lymphoma
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
